NCT03053804

Brief Summary

It is a study that hypothesize that MR/PET can have better information than current CT image study, about the medical or surgical treatment outcome of lung cancer

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
75

participants targeted

Target at P50-P75 for not_applicable nonsmall-cell-lung-cancer

Timeline
Completed

Started Mar 2015

Typical duration for not_applicable nonsmall-cell-lung-cancer

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2015

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

October 30, 2016

Completed
4 months until next milestone

First Posted

Study publicly available on registry

February 15, 2017

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2018

Completed
Last Updated

February 15, 2017

Status Verified

November 1, 2016

Enrollment Period

3.8 years

First QC Date

October 30, 2016

Last Update Submit

February 14, 2017

Conditions

Non-small Cell Lung Cancer

Keywords

MR/PETNon-small cell lung cancer (NSCLC)

Outcome Measures

Primary Outcomes (1)

  • Change from Baseline PET/MR parameters at 2 months after treatment

    2 months after treatment

Study Arms (1)

MR/PET

EXPERIMENTAL

hypothesize that MR/PET can have better information than current CT image study

Radiation: MR/PET

Interventions

MR/PETRADIATION

MR/PET with contrast media and FDG-18

MR/PET

Eligibility Criteria

Age20 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age: \> 20 years old.
  • Patients have confirmed lung cancer by histopathological methods (fiber, bronchoscopy, lung biopsy, open chest biopsy, pleural effusion exfoliated cells, sputum exfoliated cells)
  • Patients voluntarily to join this study and signed informed consents.

You may not qualify if:

  • Any body metal implants (pacemaker implantation, nerve stimulator, vascular stent, aneurysm clip, eye foreign body, the inner metal prosthesis) or artificial heart valves
  • Patients with claustrophobia to MRI examination
  • Patients who are reluctant to comply with follow-up and subsequent examination
  • Pregnancy.
  • Age \< 20 years old.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Taiwan University Hospital

Taipei, Taipei, 100, Taiwan

RECRUITING

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Yeun-Chung Chang, MD

    National Taiwan University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Yeun-Chung Chang

CONTACT

02-23123456*65566ycc5566@ntu.edu.tw

Yu-Sen Huang

CONTACT

02-23123456*65566yusen0814@gmail.com

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 30, 2016

First Posted

February 15, 2017

Study Start

March 1, 2015

Primary Completion

December 1, 2018

Study Completion

December 1, 2018

Last Updated

February 15, 2017

Record last verified: 2016-11

Data Sharing

IPD Sharing
Will not share

Locations

TW(1)